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ABSTRACT
Background. Melanoma in-transit metastases (ITMs) are
a challenge to treat and associated with systemic disease
and poor prognosis. Topical diphencyprone (DPCP), a
potent contact sensitizer, is an established treatment for
melanoma ITMs. This exploratory study investigated the
utility of BRAF mutation status, CD8, PD-1, PD-L1, and
TILs distribution as biomarkers for response of ITMs to
topical immunotherapy (DPCP).
Methods. The ITM deposits of 40 patients treated with
DPCP were subjected to biomarker analysis for BRAF
status, CD8 and PD-1 expression on tumor-infiltrating
lymphocytes (TILs), and tumor PD-L1 expression.
Response to DPCP and overall survival (OS) were com-
pared by biomarker status.
Results. After 12 weeks, 10 patients (25%) had a com-
plete response, 12 patients (30%) had a partial response,
and 18 patients (45%) had no response. No significant
association was found between any individual biomarker
and response to DPCP or OS. The BRAF mutation rate was
25% (10/40). All the patients with a complete response had
BRAF wild-type tumor. Peritumoral CD8? T-cells were
associated with complete response (P = 0.041). Both
CD8? and PD-1 expressions were highly correlated
(P\ 0.0001), and the highest levels of PD-1 expression
were detected at the peritumoral interface (P = 0.0004).
Only two cases were PD-L1-positive, and both had a
complete response to DPCP (P = 0.043).
Conclusion. Patients who have BRAF wild-type tumor are
more likely to experience a complete response to DPCP.
Peritumoral TILs and PD-1 expressions may predict a
better response to DPCP. Expression of PD-L1 may be
associated with a complete response to DPCP. A larger
prospective study is required.
In-transit metastases (ITMs) occur in up to 12% of
patients with a diagnosis of cutaneous melanoma.1 The
ITMs are locally recurrent deposits of melanoma located
predominantly in the dermal and subdermal lymphatics
between the primary and draining lymph nodes. In-transit
metastases are challenging to treat, presenting heteroge-
neously from a single large lesion to multiple superficial
papules (0.2–2 cm), erythematous or pigmented. The
lesions continue to grow in size and number, eventually
causing significant morbidity to patients.
Normally, ITMs occur in the first 36 months after
diagnosis of the original primary tumor, and patients usu-
ally have no other distant metastases at the time of
presentation.1,2 An ITM occurring in isolation represents
advanced stage 3 disease according to the latest American
Joint Committee on Cancer (AJCC) staging system for
melanoma, with an overall 5-year survival rate of 32% to
83% and a 10-year survival rate of 24% to 77%.3 Many
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patients with ITMs are otherwise asymptomatic and sur-
vive for a significant period after presentation, which
means that the lesions require effective palliation, treat-
ment, or both.
Many treatment options are available for ITMs, ranging
from simple ablative procedures (e.g., surgical excision or
CO2 laser ablation) to complex locoregional therapies (e.g.,
limb infusion/perfusion or systemic therapy).2,4 Topical
immunotherapy is a convenient, first-line therapy for
patients with low-burden disease,5,6 and the agent of choice
in our center is diphencyprone (DPCP).7
The topical immunotherapy agent, DPCP, was first
reported as a treatment for melanoma metastases in 1989.8
As a hapten, DPCP elicits a CD8? T-cell-mediated,
delayed hypersensitivity response, which in turn stimulates
the release of cytokines, specifically IL-24 and IL-9, which
are known to act in melanoma as tumor-suppressor
cytokines promoting lymphocyte-mediated tumor
destruction.9
A potent contact sensitizer, DPCP causes delayed
hypersensitivity reactions in 98% of people.10 Once sen-
sitized, patients apply DPCP cream to lesions once weekly,
inducing a local inflammatory reaction.11 Patients tolerate
DPCP well with no systemic side effects. Our long-term
outcomes with this therapy have been previously reported.7
The most prevalent gene identified in melanoma is the
mutation of the proto-oncogene BRAF, present in 41% to
56% of all melanomas.12 This mutated protein is impli-
cated in different means of melanoma progression,
including activation of the MEK/ERK pathway, evading
the immune response, senescence, and apoptosis as well as
angiogenesis, tissue invasion, and metastasis.13,14 In 2010,
BRAF mutation was first described as a therapeutic target
and currently is the standard of care for
suitable patients.15,16
Importantly, CD8? cytotoxic T lymphocytes recognize
tumor-associated antigens presented by tumor cells on their
surface with major histocompatibility complex class 1
molecules (MHC I). Cytotoxic T cells demonstrate clini-
cally significant anti-tumor activity in melanoma.17
Infiltration of CD8?, generally associated with improved
survival, is a good prognostic marker.18 The programmed
cell death 1 (PD-1) immune inhibitory receptor is present
on T- and B-lymphocytes, natural killer cells, and myeloid
cells, and PD-L1 is its corresponding ligand expressed on
tumor cells, T and B cells, macrophages, and dendritic
cells.19 The PD-1/PD-L1 interaction is a recognized
mechanism whereby malignant cells evade the immune
system to allow tumor growth and progression. High levels
of PD-L1 expression in tumors are associated with a poorer
prognosis.20 The blockade of the PD-1 pathway is per-
formed in melanoma treatment with the use of systemic
anti-PD1 therapy.21,22
The current study aimed to evaluate any link between
the expression of BRAF mutation, CD8, PD-1, and PD-L1
in ITMs and clinical response to DPCP.
METHODS
Patients who had biopsy-proven ITMs treated with
DPCP at our quaternary referral cancer center between
2008 and 2016 were identified from our institutional mel-
anoma database. Patients with AJCC stage 3 melanoma at
the time of presentation who had unresectable low-volume
disease (superficial small metastatic deposits in the dermis
and subcutis) were triaged to DPCP as first-line therapy by
the assessing clinicians and the Specialist Multidisciplinary
Team (MDT).
The treatment protocol for ITMs with DPCP has been
previously described.5,7 In brief, the patients were initially
sensitized to DPCP in the clinic, and once contact sensi-
tivity was confirmed, the patients were started on a once-
weekly regimen of 0.05% topical DPCP applied to the area
under the direction of the treating clinician in the patient’s
home. The patients were monitored every 2 weeks to gauge
their clinical reaction to the DPCP, and the concentration
of the agent was modified accordingly. The maintenance
concentration of DPCP used varied from 0.000001 to
0.05%.
Clinical response to treatment was assessed and recor-
ded by the senior clinician (J.J.G.) in a combined MDT
clinic, in which a contemporaneous second opinion from
other clinicians was available if the lack of clinical
response was concerning or other simultaneous treatment
methods were needed (e.g., surgical excision, CO2 laser
ablation, or systemic therapy) in case of a partial response.
Clinical responses were recorded 3 and 6 months after the
initiation of treatment with DPCP and graded CR (com-
plete response with no viable tumor observed), PR (partial
response with some, but not all, of the tumor resolved), or
NR (none, with none of the presenting ITMs showing a
response to the DPCP or with the development of more
ITMs and no evidence of a response). The total response
rate was calculated as CR ? PR/all patients 9 100%.
Treatment was continued for at least 12 months if the
patient responded or discontinued if the disease showed
obvious uncontrolled progression.
Immunohistochemistry and Molecular Diagnostics
Archived formalin-fixed, paraffin-embedded surgical
histology specimens of in-transit metastases were retrieved.
Histology was reviewed on hematoxylin and eosin (H&E)
slides, and a single representative block was chosen for
immunohistochemistry (IHC). Before the start of DPCP
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treatment, 34 specimens (85%) were taken, and 6 further
samples (15%) were taken afterward.
All IHC was performed on an Leica bond immunos-
tainer (Leica Microsystems (UK) Ltd, Milton Keynes, UK)
according to the manufacturer’s instructions. Testing of
BRAF mutation was performed according to our clinical
standard of care, which has been published elsewhere.23
For BRAF V600E IHC, Pleasanton, CA Spring Bioscience
mouse anti-human BRAF V600E monoclonal antibody
(Clone VE1) was used at a dilution of 1:200 run on a
routine long program.
The BRAF V600E IHC was reported as positive or
negative. Any negative specimens or specimens displaying
variable expression underwent molecular diagnostic testing
(Biocartis Idylla system; PCR, Mechelen, Belgium) to
identify other BRAF V600 mutations.
For CD8 IHC, Leica 4B11 clone CD8-4B11-L-CE was
used at 1:40 dilution on a routine heat retrieval program.
For PD-1 IHC, Cell Marque PD-1 EP239 (315R-14),
Rocklin, CA was used at 1:250 dilution on a routine heat
retrieval program. Positive control for CD8 and PD-1
included tonsillar tissue. For PD-L1 IHC, Cell Marque PD-
L1 28-8 (438R-14-ASR) was used at 1:75 dilution on a
long heat-retrieval program. We used PD-L1-positive cell
lines, and positive control included endometrial and ton-
sillar tissue. Every batch of IHC was run with a satisfactory
control line.
Expression of CD8 and PD-1 on positive TILs within
tumor nests was reported per square millimeter in the area
of the most dense lymphocyte infiltration at high-power
(940) fields. The counts per square millimeter were
grouped into the following levels of expression: 0 (0 cells/
mm2), 1 (1–10 cells/mm2), 2 (11–100 cells/mm2), and 3
(C 101 cells/mm2). Expression of PD-L1 was seen on
tumor cells and immune cells. To provide percentage of
expression, PD-L1-positive tumor cells were counted, and
5% or higher was considered as indicating PD-L1
positivity.
Detection and observer bias was avoided in this study
due to blinding of researchers analyzing the specimen
slides to any clinical data.
Spatial Distribution of CD8? TILs
The location of the TILs in relation to the tumor deposit
was assessed using both the H&E stains and CD8
immunostains and classified into three distinct patterns
based on the distribution of the CD8? lymphocytes as
follows: peripheral/absent (lymphocytes predominantly
located in the perivascular region or absent altogether),
peritumoral (lymphocytes predominantly located at the
tumor edge/margin or tumor-stroma interface), or intratu-
moral (lymphocytes predominantly located within the
tumor, with few or no lymphocytes in the peritumoral
location). Figure 1 shows representative examples of each
pattern.
Statistical Analysis
Biomarker status was tabulated by response group. Chi
square tests and Fisher’s Exact Test were used to establish
association between biomarker status and response to
DPCP. The Kaplan-Meier log-rank method was used for
survival estimates and graphic representation. Analysis was
performed with GraphPad Prism v. 8.0 (GraphPad.com,
San Diego, CA, USA).
RESULTS
Ethics approval was granted for this study (IRAS ID:
227816; Cambridge Regional Ethics 17/EE/0451). The
cohort of 40 patients treated between 2008 and 2016 with
samples eligible for biomarker analysis included 22 women
(55%) and 18 men (45%). The cohort had a median age of
76 years (range, 47–95 years). After 12 weeks of treatment
with DPCP, 10 patients (25%) had CR, 12 had PR (30%),
and 18 (45%) had NR, for an overall response (CR?PR) of
55%. The median OS was 26 months (range, 2–79 months)
(Fig. 1a). During the study period, 24 patients died. The
median progression-free survival (PFS) was 6 months
(Fig. 2b). A clinical response to DPCP was significantly
associated with increased OS (P = 0.0021) and PFS
(P\ 0.0001) (Fig. 2c and d) (Table 1).
Biomarker Distribution and Analysis
All identified BRAF mutations were of the V600E sub-
type. The 40 specimens comprised 10 (25%) BRAF V600E
mutation-positive and 30 (75%) BRAF mutation–wild-type
specimens. Table 2 shows the distribution of the lympho-
cyte biomarkers according to BRAF status. No significant
association was observed between BRAF mutation status
and CD8?, PD-1, or PD-L1 counts. The distribution of the
TILs was not associated with BRAF status.
Lymphocyte Biomarkers and TILs Distribution
Table 3 shows the biomarker TILs distribution analyses.
A strong association with PD-1 and CD8 counts was
observed (P\ 0.0001, Fisher’s Exact Test). A Chi square
test for trend indicated a significant association between the
two-variables (P\ 0.0001). The predominant TILs pat-
terns were evenly distributed among the three subgroups.
The PD-1 cell counts were significantly associated with
TILs distribution (P = 0.0004). A significant trend toward
Quantitative and Spatial Analysis of CD8?/PD-1 Tumor-Infiltrating Lymphocytes as a… 1031
the peritumoral TILs pattern was observed, demonstrating
higher PD-1 cell counts (P = 0.0012). Tumors with pre-
dominantly peritumoral TILs demonstrated high PD-1 cell
counts ([ 10 cells/mm2) in more than half (58.3%) of the
specimens analyzed, whereas the PD-1 cell counts in the
absent/peripheral and intratumoral TILs groups were low
(B 10 cells/mm2) for the majority of specimens (16.7% and
6.2%, respectively; P = 0.006).
Response to DPCP and Biomarker Status
All the patients with a CR had a BRAF wild-type tumor
(Table 4). The presence of a BRAF V600E mutation was
associated with a poor clinical response (P = 0.025). The
responding groups (CR?PR) showed a trend for higher
overall CD8? counts, but this was not statistically signif-
icant (P = 0.165). Increasing PD-1 cell counts were
associated with a better response to DPCP (P = 0.042).
Although only two tumors demonstrated measurable PD-
FIG. 1 A CD8? peripheral/absent TILs (9 1); B peripheral/absent PD-1 TILs (9 1); C CD8? peritumoral TILs (9 1); D PD-1? peritumoral
TILs (9 1); E CD8? intratumoral TILs (9 1); F PD-1? intratumoral TILs (9 1)
1032 S. Haywood et al.
L1, the presence of this receptor was significantly associ-
ated with a CR (P = 0.043). Table 5 shows that although
no significant association was demonstrated with CD8?
TILs distribution and response to DPCP (P = 0.1281),
subanalysis showed that peritumoral CD8? TILs were
associated with a favorable response to DPCP
(P = 0.0421). Similarly, 60% of the CRs were associated
with tumors that demonstrated this distribution, which was
significant (P = 0.0410). Other patterns of CD8? TILs















































































































FIG. 2 a Overall survival. b Progression-free survival. c Comparison of OS between responders and non-responders. d Comparison of PFS
between responders and non-responders
TABLE 1 Response to DPCP correlated with OS and PFS
Response n (%) Median OS Months (IQR) Deaths (n) HR (95% CI) P Valuea
NR
CR or PR 18 (45) 14.0 (7.0– 27.0) 14 0.3153 0.0021
22 (55) 61.0 (25.0–NtR) 10 (0.132–0.751)
Response n (%) Median PFS Months (IQR) Recurrences (n) HR P Value
NR response
CR or PR 18 (45%) 4.0 (2.0–5.5) 18 0.2703 \0.0001
22 (55%) 21.0 (6.0–34.0) 15 (0.119–0.612)
DPCP diphencyprone, OS overall survival, PFS progression-free survival, IQR interquartile range, HR hazard ratio, NR no response, PR partial
response, CR complete response, NtR not reached
aLog-rank test
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PD-1 cell count (B 10 cells/mm2) was associated with
significantly low complete response rates compared to
diphencyprone (low rates of CR to DPCP) compared with a
high PD-1 cell count (13.3% vs 60%; P = 0.0061).
None of the biomarkers investigated in this study were
associated with overall survival (OS) of the patients in this
cohort (Table 4).
DISCUSSION
The response to DPCP and the survival rates are in
keeping with the results published by the current group,7
two Australian cohorts,5,6 and two smaller Canadian and
Brazilian cohorts.24,25 Collation of the published data for
192 patients to date shows that DPCP has an overall
response (CR ? PR) rate of 64.6%. The findings showed an
overall CR of 30.7% (range, 13–46%), an overall PR of
33.9% (range, 25–38.9%), and an NR rate of 35.4% (range,
18–60%).
TABLE 2 Lymphocyte biomarkers and distribution by BRAF mutation status
Variable Category BRAF wild type (n = 30) BRAF V600E (n = 10) Total n (%) P Valuea
CD8? \ 1 3 3 6 (15) 0.3186
(cells/mm2) 1–10 12 2 14 (35)
11–100 9 4 13 (32.5)
[ 100 6 1 7 (17.5)
PD-1 \ 1 12 3 15 (37.5) 0.8281
(cells/mm2) 1–10 10 5 15 (37.5)
11–100 4 1 5 (12.5)
[ 100 4 1 5 (12.5)
Predominant TILs Absent/peripheral 9 3 12 (30) 0.6778
Distribution Peritumoral 10 2 12 (30)
Intratumoral 11 5 16 (40)
Tumor PD-L1 B 5% 28 10 38 (95) 0.4020
[ 5% 2 0 2 (5)
PD-1 programmed cell death 1, TILs tumor-infiltrating lymphocytes, PD-L1 programmed death-ligand 1
aFisher’s Exact Test
TABLE 3 CD8? lymphocyte count, TILs location, and PD-1 biomarker status
VARIABLE Category PD-1 (cells/mm2)
\ 1 1–10 11–100 [ 100 Total n (%) P Value
CD8? count \ 1 4 1 1 0 6 (15)
(cells/mm2) 1–10 9 5 0 0 14 (35) \ 0.0001a
11–100 2 8 3 0 13 (32.5) \ 0.0001b
[ 100 0 1 1 5 7 (17.5)
TILs location Absent/peripheral 8 2 2 0 12 (30)
Peritumoral 0 5 2 5 12 (30) 0.0004a
Intratumoral 7 8 1 0 16 (40) 0.0012b
Low PD-1 (B 10 cells/mm2) n (%) High PD-1 ([ 10 cells/mm2) n (%)
TILs location Absent/peripheral 10 (83.3) 2 (16.7) 12 (30%)
Peritumoral 5 (41.7) 7 (58.3) 12 (30%) 0.0060a
Intratumoral 15 (93.8) 1 (6.2) 16 (40%) 0.0051b
TILs tumor-infiltrating lymphocytes, PD-1 programmed cell death 1
aFisher’s Exact Test
bChi square test for trend
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BRAF V600E Mutation Status
Read et al.6 reported a BRAF V600 mutation rate of
26.9% in a similar cohort of patients with ITMs but did not
comment in its relation to DPCP response. This is close to
the current study’s positive mutation rate of 25%. These
two independent cohorts of patients with ITMs demonstrate
a lower rate of BRAF positivity than the expected rate of
50% for all melanomas. One interpretation maintains that
BRAF V600 mutant tumors are less likely to develop ITMs,
although further cohorts are required to verify this. Adler
et al.26 reported that in BRAF-mutant patients, lymph node
metastases are more likely to develop as first metastases
than as in-transit metastases but do not report the rate of
BRAF mutation in their group with ITMs. In this study, all
10 patients with a CR were BRAF wild type (P = 0.025),
although BRAF status was not significantly associated with
OS or PFS (P = 0.43). Notably, targeted systemic therapy
was historically unavailable to most of the patients in our
cohort. Therefore, it is not possible to draw any reasonable
conclusions from our data alone. Other studies have
reported that a BRAF V600 mutation is associated with
higher metastatic burden, suggested that it is an indepen-
dent negative prognostic factor for OS and distant
metastasis-free survival.27–29
CD8? PD-1 TILs and the Tumor Microenvironment
A significant presence of T cells identified in the tumor
microenvironment (TME) generally is associated with a
good prognosis.18 In particular, CD8? TILs are associated
with improved RFS and OS for melanoma, which may be
closely related to the directly killing effect of CD8? TILs
on tumor cells.30 The TME consists of cancer cells,
inflammatory cells, stromal cells, and cytokines, and these
components form a complicated immunosuppressive net-
work in cancer, which limits T cell activation and induces
T cell dysfunction. The PD-L1/PD-1-signaling pathway is
a crucial regulatory pathway of T cell exhaustion in cancer,
and PD-L1 is abundantly expressed in cancer cells and
stromal cells. A marker of T cell exhaustion is the upreg-
ulation of the PD-1 receptor.31
Our results after simple profiling of the TME of ITMs,
highlight the complexity of these interactions. Unlike
previous TILs studies of primary melanoma, our data did
not show a quantitative relationship between CD8? T-cell
count and response to therapy or OS. However, qualitative
analysis of the TILs distribution showed that the predom-
inant presence of CD8? T cells at the stromal-tumor
interface of the ITM is associated with significantly
increased rates of response to the topical immunotherapy.
Similarly, our data demonstrate that at that same location, a
significantly greater proportion of PD-1 CD8? cells exist,
suggesting underlying mechanisms of localized immuno-
suppression at the stromal-tumor interface of the ITM that
promote T cell exhaustion and prevent tumor destruc-
tion.31,32 Given that a delayed hypersensitivity reaction
produced by the application of DPCP generates a dramatic
influx of CD8? cytotoxic T cells local to the ITMs,9,33 we
hypothesize that the mechanism of the topical
immunotherapy action is to overwhelm the TME with
active CD8? T-cells, thereby shifting the balance in favor
TABLE 4 Clinical response to DPCP correlated with OS by biomarker status
Variable Category CR n PR n NR n Total n (%) P Valuea Median OS Months (IQR) Deaths (n) P Valueb
BRAF Wild type 10 6 14 30 (75) 0.025 25.0 (9.0–39.0) 17 0.412
V600E 0 6 4 10 (25) 17.5 (14.0–26.0) 7
CD8? \ 1 1 3 2 6 (15) 0.165 18.5 (7.0–49.0) 3 0.752
(cells/mm2) 1–10 3 2 9 14 (35) 25.0 (9.0–30.0) 11
11–100 2 6 5 13 (32.5) 25.0 (14.0–34.0) 8
[ 100 4 1 2 7 (17.5) 17.0 (10.0–26.0) 2
PD-1 \ 1 1 5 9 15 (37.5) 0.042 25.0 (8.0–44.0) 10 0.706
(cells/mm2) 1–10 3 4 8 15 (37.5) 20.0 (14.0–32.0) 10
11–100 2 2 1 5 (12.5) 34.0 (18.0–49.0) 3
[ 100 4 1 0 5 (12.5) 17.0 (15.0–17.0) 1
Tumor PD-L1 B 5% 8 12 18 38 (95) 0.043 19.5 (10.0–32.0) 22 0.919
[ 5% 2 0 0 2 (5) 47.5 (34.0–61.0) 2
DPCP diphencyprone, OS overall survival, CR complete response, PR partial response, NR no response, IQR interquartile range, PD-1
programmed cell death 1, PD-L1 programmed death-ligand 1
aChi square test for trend
bLog-rank test
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of tumor destruction rather than PD-L1/PD-1 immuno-
suppression at the tumor-stromal interface.
Conversely, ITMs located in an immunologically
‘‘bland’’ TME associated with the BRAF V600E mutation
and characterized by absent or predominantly intra-tumoral
T cells and low PD-1 expression did not benefit from the
localized inflammation induced by the hypersensitivity
reaction and did not respond to DPCP. We noted with
interest that in addition to the pooled international data, the
proportionate distribution of CD8? TILs closely mirrored
the rate of the response to DPCP in our study, although this
may have been coincidental and requires much
investigation.
Notably, the rate of response to DPCP was heavily
correlated with PFS (P = 0.0021) and OS (P\ 0.0001)
(Table 1), which raises the possibility that the same TME
immune interactions are mirrored at metastatic sites. Cor-
relation studies with systemic immunotherapy outcomes
would be clinically useful because this would indicate that
ITMs could potentially be studied as a translational model
for systemic response to novel therapies.
PD-L1 Expression
The result of two PD-L1-positive cases is surprising
because PD-L1 expression is reported in up to 40% of
melanoma cases, in both primary and metastatic
lesions.20,34,35 The data from a recent meta-analysis of
multiple solid tumors showed that PD-L1 overexpression is
associated with worse disease-free and progression-free
survival in melanoma (hazard ratio [HR], 3.39; 95% con-
fidence interval [CI], 2.02–5.69; P\ 0.0001).36
Study limitations
This study had several limitations including its small
sample size and possible selection bias in a non-random-
ized cohort. In particular, the multifocal and heterogeneous
nature of the condition meant that the true burden of the
disease could not be accurately measured or classified and
that the single biopsy analyzed may not have been reflec-
tive for all the ITMs in the region. In addition,
measurement of clinical response is necessarily subjective
and has historically been an issue common for many
studies investigating treatment for ITMs.4,37,38
Regarding the analyses, this was an exploratory study
with limited resources. Therefore, our T cell subset was
TABLE 5 Predominant CD8? TILs location subanalysis and response to DPCP
Variable Category CR (n) PR (n) NR (n) P Value
Lymphocyte response
TILs location Absent/peripheral 3 3 6 0.1281a
Peritumoral 6 3 3
Intratumoral 1 6 9
TILs location Peritumoral 6 3 3 0.0421a
(subanalysis) Peripheral or intratumoral 4 9 1 0.0172b
Variable Category CR PR or NR P Value
TILs location Peritumoral 6 6 0.0410a
(subanalysis) Peripheral or intratumoral 4 24
Variable Category CR PR NR P Value
PD-1 Low (B 10) 4 9 17 0.0061a
(cells/ mm2) High ([ 10) 6 3 1 0.0062b
(All TILs)
PD-1 Low (B 10) 1 1 3 0.0985a
(cells/mm2) High ([ 10) 5 2 0 0.0542b
(peritumoral TILs)
TILs tumor-infiltrating lymphocytes, DPCP diphencyprone, CR complete response, PR partial response, NR no response, PD-1 programmed cell
death 1
aChi square test
bChi square test for trend
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limited to CD8. The study would have been improved by
additional T cell marker analyses, particularly analyses of
CD3, CD4, and CD31, with cytokine assays to complement
this work. Our sample was relatively small, and although
we demonstrated significant findings in subanalyses, the
group sizes were smaller, and the findings in this study
should perhaps not be overstated. However, significant
findings in small samples are challenging to achieve and, as
such, the results appear to be compelling.
Finally, the results of patient outcomes were collated
mostly in a period before the general availability of sys-
temic immunotherapy. It would be interesting in future
studies to correlate the response to local immunotherapy
with the response to systemic immunotherapy.
CONCLUSION
The study findings indicate that the tumor microenvi-
ronment plays an important role in determining the
response of melanoma ITMs to topical DPCP. The results
indicate that the absence of a BRAF V600 mutation and
PD-L1 tumor expression are associated with a favorable
response to DPCP, and qualitative assessment of CD8?
TILs may be useful for predicting the clinical outcome with
DPCP. These results may be useful for clinicians triaging
the sequence of treatments for low-burden disease. A larger
prospective study is needed for further elucidation of the
mechanisms whereby topical DPCP leads to resolution of
melanoma ITMs in the skin.
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